News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,604 Results
Type
Article (14902)
Company Profile (299)
Press Release (266397)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79840)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50697)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145081)
Policy (10075)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21764)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6030)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43663)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1102)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (49)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31643)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51658)
Executive appointments (621)
FDA (7583)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (505)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1206)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2665)
Medtech (2674)
Mergers & acquisitions (6615)
Metabolic disorders (725)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (330)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26652)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15473)
Phase 2 (20285)
Phase 3 (12819)
Pipeline (3239)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1447)
Recruiting (12)
Regulatory (9893)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (174)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1206)
Last 365 days (17801)
2026 (1651)
2025 (18099)
2024 (20547)
2023 (22415)
2022 (26823)
2021 (27805)
2020 (23361)
2019 (16230)
2018 (11741)
2017 (13750)
2016 (11844)
2015 (14352)
2014 (10394)
2013 (7484)
2012 (7532)
2011 (7617)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18263)
Australia (3110)
California (7074)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39162)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5579)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (826)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23322)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,604 Results for "hoth therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
January 5, 2026
·
6 min read
Press Releases
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
January 21, 2026
·
5 min read
Press Releases
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
January 23, 2026
·
7 min read
Press Releases
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
January 16, 2026
·
5 min read
Press Releases
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
December 2, 2025
·
3 min read
Press Releases
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
October 9, 2025
·
5 min read
Press Releases
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
December 4, 2025
·
6 min read
Press Releases
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
October 8, 2025
·
4 min read
Press Releases
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
October 22, 2025
·
6 min read
Press Releases
Hoth Therapeutics to Attend 2025 BIO International Convention
June 16, 2025
·
3 min read
1 of 28,161
Next
